Use of Metastatic Gene Signatures in the Diagnosis, Prognosis, and Treatment of Metastasis and Tumor Self-Seeding

SK1182/SK1270/SK1351/SK1375

Summary of Invention

This portfolio describes the use of metastatic gene signatures as a tool for the diagnosis, prognosis, and treatment of metastases and tumor self-seeding. Included is a method to determine the metastatic and self-seeding potential of a variety of cancers as well as screen for potential compounds that block metastasis and/or self-seeding (SK1270). The unique gene signatures which drive breast cancer metastasis to the lung and brain (SK1182/SK1351/SK1375) were identified using the methods described in SK1270. The ability to determine the unique gene signatures of metastatic cancer cells allows identification of critical regulators of metastasis and potential new therapeutic targets.

Lead Inventors

Joan Massagué, PhD, Sloan Kettering Institute Director and Laboratory Head, Cancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology, Memorial Sloan Kettering

Relevant Publications and Patent Status 

SKI Reference Title Peer-Reviewed Publication Patent Status
SK1182 Genes that mediate breast cancer metastasis to the lung Nature (2005) Vol 436 Pg 518 US Patent: 8,178,505 and US Div Application No: 13/447,684
SK1270 Assay for anti-metastatic agents Nature (2005) Vol 436 Pg 518 US Patent: 7,829,066
SK1351 Gene Signatures for the Prognosis of Breast Cancer Cell (2008) Vol 133 Pg 66 US Publication No: 2011/0053804
SK1375 Genes That Mediate Metastasis and Primary Tumor Growth Nature (2009) Vol 459 Pg 1005 US Publication No:2010/0029748

Contact Information

Imke Elhers, PhD, CLP
Senior Licensing Manager
Tel: 646-888-1074

E-mail: ehlersi@mskcc.org

Technology Types